Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 16/20 | 0.78 |
| ▸ | AKR1C2 | P52895 | 16/20 | 0.78 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701240 | 0.88 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL9594214 | 0.88 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL4229310 | 0.87 | AKR1C3 (0.74) | AKR1C3AKR1C2 | |
| SCHEMBL4216592 | 0.86 | AKR1C3 (0.65) | AKR1C3AKR1C2 | |
| SCHEMBL4223666 | 0.86 | SIRT2 (0.61) | AKR1C3AKR1C2GFER | |
| SCHEMBL11540106 | 0.85 | AKR1C3 (0.79) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL9593696 | 0.84 | AKR1C3 (0.82) | AKR1C3AKR1C2MEN1LMNAHPGD | |
| SCHEMBL4215780 | 0.84 | IGF2BP2 (0.57) | AKR1C3AKR1C2 | |
| SCHEMBL4223119 | 0.83 | AKR1C3 (0.60) | AKR1C3AKR1C2GFER | |
| SCHEMBL28404353 | 0.83 | AKR1C3 (0.81) | AKR1C3AKR1C2MEN1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | AKR1C3 105/4885AKR1C2 287/4885PDE4B 4102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.